Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Jasgit Sachdev on Antibody-Drug Conjugate PF-06647020 in Ovarian Cancer

Jasgit Sachdev, MD
Published: Monday, Oct 17, 2016


Jasgit Sachdev, MD, clinical associate professor at Translational Genomics Research Institute, discusses a phase I study of PF-06647020, an antibody-drug conjugate targeting protein tyrosine kinase 7 (PTK7) in patients with platinum-resistant ovarian cancer.
 
The study was initially designed as a dose-escalation study for patients with all advanced solid tumors. A pre-planned expansion for ovarian cancer included 27 patients that received PF-06647020.
 
The study found that PF-06647020 was well tolerated, says Sachdev. The design of the agent is novel because the antibody-drug conjugate targets PTK7 on the surface of the cancer cells.
 
There was very encouraging activity in this heavily pre-treated group of patients, with a 27% response rate, says Sachdev.
 

Jasgit Sachdev, MD, clinical associate professor at Translational Genomics Research Institute, discusses a phase I study of PF-06647020, an antibody-drug conjugate targeting protein tyrosine kinase 7 (PTK7) in patients with platinum-resistant ovarian cancer.
 
The study was initially designed as a dose-escalation study for patients with all advanced solid tumors. A pre-planned expansion for ovarian cancer included 27 patients that received PF-06647020.
 
The study found that PF-06647020 was well tolerated, says Sachdev. The design of the agent is novel because the antibody-drug conjugate targets PTK7 on the surface of the cancer cells.
 
There was very encouraging activity in this heavily pre-treated group of patients, with a 27% response rate, says Sachdev.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x